Haemonetics Reports Second Quarter and First Half Fiscal 2024 Results; Updates Fiscal 2024 Guidance

Boston, MA, November 2, 2023 - Haemonetics Corporation (NYSE: HAE) reported financial results for its second quarter and first half of fiscal 2024, which ended September 30, 2023:

    

2nd Quarter 2024

YTD 2024

n

Revenue, increase

$318 million, 7%

$630 million, 13%

n

Organic1 revenue increase

8%

14%

n

Earnings per diluted share

$0.48

$1.28

n

Adjusted earnings per diluted share

$0.99

$2.03

n

Cash flow from operating activities

$99 million

$118 million

n

Free cash flow before restructuring & restructuring related costs

$77 million

$89 million

1 Excludes the impact of currency fluctuation.

Chris Simon, Haemonetics’ CEO, stated: "In our second quarter we continued to strengthen our momentum and industry leadership, delivering growth while broadening our global presence. Our planned acquisition of OpSens, Inc. creates powerful opportunities for accelerated growth and diversification, and we are committed to supporting the long-term success of our businesses through continued strategic portfolio evolution and additional growth investments."

Second quarter fiscal 2024 revenue was $318.2 million, up 7.0% compared with the second quarter of fiscal 2023. Business unit revenue and growth rates compared with the prior year period were as follows:

Gross margin was 53.6% in the second quarter of fiscal 2024 compared with 53.1% in the second quarter of fiscal 2023. The primary drivers of the increase in the gross margin percentage were price, volume and mix, partially offset by inventory reserves, continuous growth investments and increased depreciation expense. Operating expenses as a percentage of revenue were 42.5% in the second quarter of fiscal 2024 compared with 37.4% in the second quarter of fiscal 2023. The increase in operating expenses as a percentage of revenue was primarily driven by intangible asset impairments, continuous growth investments and digital transformation costs, partially offset by lower freight costs. The Company had operating income of $35.3 million and a 11.1% operating margin in the second quarter of fiscal 2024, compared with operating income of $46.7 million and an operating margin of 15.7% in the second quarter of fiscal 2023. The income tax rates were 24% and 19% in the second quarters of fiscal 2024 and fiscal 2023, respectively. Second quarter fiscal 2024 net income and earnings per diluted share were $24.9 million and $0.48, respectively, compared with $33.2 million and $0.64, respectively, in the second quarter of fiscal 2023.

Organic revenue for the second quarter of fiscal 2024 was up 7.6% compared with the same period of fiscal 2023. Business unit organic revenue growth rates compared with the prior year period were as follows:

Second quarter fiscal 2024 adjusted gross margin was 54.0%, up 30 basis points compared with the prior year period. The primary drivers of the increase in the gross margin percentage were price, volume and mix, partially offset by inventory reserves, continuous growth investments and increased depreciation expense.

Adjusted operating expenses as a percentage of revenue were 32.6% in the second quarter of fiscal 2024, compared with 33.3% in the second quarter of fiscal 2023. The decrease in adjusted operating expenses as a percentage of revenue was primarily driven by operating leverage and lower freight costs, partially offset by continuous growth investments. Adjusted operating income for the second quarter of fiscal 2024 was $68.3 million, up $7.7 million or 12.8%, compared with the second quarter of fiscal 2023. Adjusted operating margin was 21.5%, up 110 basis points when compared with the same period of fiscal 2023. The adjusted income tax rates were 23% and 22% in the second quarters of fiscal 2024 and fiscal 2023, respectively.

Second quarter fiscal 2024 adjusted net income was $50.7 million, up $7.9 million, or 18.5%, and adjusted earnings per diluted share was $0.99, up 19.3%, when compared with the same period of fiscal 2023.

The Company recorded amortization of acquired intangible assets of $7.2 million in the second quarter of fiscal 2024 compared with $8.2 million in the second quarter of fiscal 2023. The Company also incurred $3.6 million of digital transformation costs related to the upgrade of our enterprise resource planning system in the second quarter of fiscal 2024.

An intangible asset impairment charge of $10.4 million was recorded during the second quarter of fiscal 2024 related to the intangibles acquired as part of the enicor GmbH acquisition completed in fiscal 2021.

Cash on hand at September 30, 2023 was $351.0 million, an increase of $66.5 million since April 1, 2023.

Cash flow from operating activities was $99.1 million and free cash flow before restructuring and restructuring related costs was $76.7 million during the second quarter of fiscal 2024, compared with $87.0 million and $61.8 million, respectively, in the same period of fiscal 2023.

The Company updated its previous fiscal 2024 GAAP total revenue and organic revenue growth guidance as follows:

Additionally, the Company updated its adjusted operating margin guidance, adjusted earnings per diluted share guidance and free cash flow before restructuring and restructuring related costs guidance, shown below.

The increase in free cash flow guidance before restructuring and restructuring-related costs is due to benefits from working capital and changes in capital expenditures, which were understated in our previously issued guidance.

The Company will host a conference call with investors and analysts to discuss second quarter fiscal 2024 results on Thursday, November 2, 2023 at 8:00 a.m. ET. The call can be accessed via teleconference at https://register.vevent.com/register/BI1dcb961b02424b85998e357a476fc7bf. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.

Alternatively, a live webcast of the call can be accessed on Haemonetics’ investor relations website at the following direct link: https://edge.media-server.com/mmc/p/twgnwbaw

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without limitation, statements regarding (i) plans and objectives of management for operations of the Company, including plans or objectives related to the development and commercialization of, and regulatory approvals related to, the Company’s products and plans or objectives related to the Operational Excellence Program; (ii) estimates or projections of financial results, financial condition, capital expenditures, capital structure or other financial items, including with respect to the share repurchase program; (iii) the impact of inflationary pressures in our global manufacturing and supply chain; and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties.

Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, availability and demand for the Company’s products; the Company’s ability to implement as planned and realize estimated cost savings from the Operational Excellence Program; inflationary pressures, rising interest rates and macroeconomic conditions; the Company’s ability to execute business continuity plans; risks arising from planned or completed acquisitions or divestitures by the Company, including any failure to realize the anticipated strategic benefits and opportunities of the transaction; the impact of share repurchases on the Company’s stock price and volatility as well as the effect of short-term price fluctuations on the share repurchase program’s effectiveness; technological advances in the medical field and standards for transfusion medicine and the Company’s ability to successfully offer products that incorporate such advances and standards; product quality; market acceptance; regulatory uncertainties, including in the receipt or timing of regulatory approvals; the effect of economic and political conditions; the impact of competitive products and pricing; blood product reimbursement policies and practices; and the effect of industry consolidation as seen in the plasma market. These and other factors are identified and described in more detail in the Company’s periodic reports and other filings with the U.S. Securities and Exchange Commission (the “SEC”). The Company does not undertake to update these forward-looking statements.

This press release contains financial measures that are considered “non-GAAP” financial measures under applicable SEC rules and regulations. Management uses non-GAAP measures to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results. Performance targets for management are also based on certain non-GAAP financial measures. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with U.S. GAAP. In this release, supplemental non-GAAP measures have been provided to assist investors in evaluating the performance of the Company’s core operations and provide a baseline for analyzing trends in the Company’s underlying businesses. We strongly encourage investors to review the Company’s financial statements and publicly-filed reports in their entirety and not rely on any single financial measure.

When used in this release, organic revenue growth excludes the impact of currency fluctuation. Adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted provision for income taxes, adjusted net income and adjusted earnings per diluted share exclude restructuring costs, restructuring related costs, digital transformation costs, amortization of acquired intangible assets, asset impairments, accelerated device depreciation and related costs, costs related to compliance with the European Union Medical Device Regulation ("MDR") and In Vitro Diagnostic Regulation ("IVDR"), integration and transaction costs, certain tax settlements and unusual or infrequent and material litigation-related charges. Adjusted net income and adjusted earnings per diluted share also exclude the tax impact of these items. The adjustments to provision for income taxes are calculated based on the jurisdictions in which pre-tax adjustments occurred. Free cash flow before restructuring and restructuring related costs is defined as cash provided by operating activities less capital expenditures, net of the proceeds from the sale of property, plant and equipment and restructuring and restructuring related costs, net of tax. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to similarly titled measures used by other companies.

A reconciliation of non-GAAP historical financial measures to their most comparable GAAP measure are included at the end of the financial sections of this press release as well as on the Company’s website at www.haemonetics.com. The Company does not provide a quantitative reconciliation of its forward-looking organic revenue growth guidance by business unit to the comparable GAAP measure because forecasting the impact of foreign currency fluctuations by business unit is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. Additionally, the Company does not attempt to provide reconciliations of forward-looking adjusted operating margin guidance, adjusted earnings per diluted share guidance or free cash flow before restructuring and restructuring related costs guidance to the comparable GAAP measures because the combined impact and timing of recognition of certain potential charges or gains, such as restructuring costs and impairment charges, is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of the Company’s financial performance.